Protective effect of pentoxifylline plus thalidomide against septic shock in mice.
Mortality caused by septic shock in experimental animals is reduced by thalidomide, an inhibitor of tumour necrosis factor alpha. Another drug that could act on the pathophysiological mechanisms of septic shock is pentoxifylline, an inhibitor of platelet aggregation that increases the flexibility of the erythrocyte membrane and has fibrinolytic activity. We studied the effect of pentoxifylline alone and combined with thalidomide in septic shock; 97 NIH mice were injected with lipopolysaccharides of Salmonella abortus equi and D galactosamine. Animals were separated in 4 groups; group A (n = 20) was used as control, group B (n = 15) received thalidomide 50 mg/kg, group C (n = 20) received pentoxifylline 40 mg/kg, and group D (n = 15) received thalidomide plus pentoxifylline. Mortality was recorded every hour. Additionally, 5 animals from each group were sacrificed 8 h after the induction of septic shock for histological analysis of heart, lung, brain, kidney, small intestine, adrenal glands and liver. Microscopic findings were rated as absent, mild, moderate and severe damage. In control animals histological analysis showed intense haemorrhage and necrosis in all organs studied. When compared with controls, treatment with pentoxifylline plus thalidomide reduced mortality (P < 0.03). The tissue damage was less severe in animals from the groups that received pentoxifylline or pentoxifylline plus thalidomide (P < 0.05). Pentoxifylline seems to potentiate the beneficial effects of thalidomide, reducing mortality and attenuating the pathological changes produced by septic shock.
Arrieta
O
O
Neuroimmunology Unit and Experimental Pathology Laboratory, Instituto Nacional de Neurología y Neurocirugía and Universidad Nacional Autónoma de México. ogar@servidor.unam.mx
Ortiz-Reyes
A
A
Rembao
D
D
Calvillo
M
M
Rivera
E
E
Sotelo
J
J
D000818:Animals; D004359:Drug Therapy, Combination; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007668:Kidney / Q000473:pathology; D008099:Liver / Q000473:pathology; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D010431:Pentoxifylline / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D012772:Shock, Septic / Q000473:pathology / Q000517:prevention & control*; D015996:Survival Rate; D013792:Thalidomide / Q000627:therapeutic use*
D007166:Immunosuppressive Agents; D010975:Platelet Aggregation Inhibitors; D013792:Thalidomide; D010431:Pentoxifylline